ABSTRACT

Sjögren syndrome (SS) is a chronic autoimmune disorder that primarily targets the salivary and lacrimal glands. The pathology of these exocrine glands is characterized by periductal focal lymphocytic infiltrates, and both T cell-mediated tissue injury and autoantibodies that interfere with the secretion process underlie glandular hypofunction. In addition to these adaptive mechanisms, multiple innate immune pathways are dysregulated, particularly in the salivary gland epithelium. Our understanding of the pathogenetic mechanisms of SS has substantially improved during the past decade. In contrast to viral infection, bacterial infection has never been considered in the pathogenesis of SS. In this review, oral dysbiosis associated with SS and evidence for bacterial infection of the salivary glands in SS were reviewed. In addition, the potential contributions of bacterial infection to innate activation of ductal epithelial cells, plasmacytoid dendritic cells, and B cells and to the breach of tolerance via bystander activation of autoreactive T cells and molecular mimicry were discussed. The added roles of bacteria may extend our understanding of the pathogenetic mechanisms and therapeutic approaches for this autoimmune exocrinopathy.

Keywords: Sjogren syndrome; Oral; Bacteria; Dysbiosis; Salivary gland; Pathogenesis

INTRODUCTION

Primary Sjögren syndrome (SS) is a systemic autoimmune disorder of unknown etiology that primarily targets the salivary and lacrimal glands, leading to ocular and oral dryness. Together with dryness, musculoskeletal pain and fatigue constitute the classic symptom triad. Approximately 30%–40% of patients develop extraglandular manifestations involving the joints, lung, kidney, or nervous system. SS mainly affects perimenopausal women with a 9:1 female dominance (1).

The pathology of the affected exocrine glands is characterized by periductal lymphocytic infiltrates called focal lymphocytic sialadenitis (FLS), which can develop into ectopic lymphoid structures (2). Another hallmark of SS pathology is B cell hyperactivity characterized by polyclonal hypergammaglobulinemia, increased levels of free light chains, production of diverse autoantibodies, and an increased risk of developing B cell lymphoma.
Autoantibodies detected in patients with SS include antinuclear antibodies (ANA), rheumatoid factor (RF), anti-SS-related antigen A (SSA; also known as Ro comprised with 2 ribonucleoproteins, Ro52 and Ro60) antibodies, and anti-SS-related antigen B (SSB; also known as La) antibodies that are the traditional biomarkers of SS but are also found in other systemic autoimmune diseases. Except for the RF that targets IgG, the autoantigens targeted by ANA, anti-SSA, or anti-SSB are ubiquitously expressed in all mammalian cells. Numerous autoantibodies have been additionally identified in SS, including those against molecules more specifically expressed in the target organs, such as salivary protein 1, carbonic anhydrase 6, parotid secretory protein, aquaporin 5 (AQP5), and type 3 muscarinic acetylcholine receptor (4).

Similar to other common autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, SS is a multifactorial disease involving both genetic and environmental factors. The most common environmental factor for autoimmune disease development is an infection. Because of the prominent type I IFN signature found in the peripheral blood of patients with SS, viral infection has long been speculated to be a triggering factor of SS.

The ducts of the salivary glands open into the oral cavity; thus, crosstalk between the salivary glands and oral microbiome is inevitable. Dysbiosis of the oral microbiota in SS has been reported, but its connection to the etiopathogenesis of SS is not fully appreciated. In this review, we discuss how the oral microbiota can contribute to the pathogenesis of SS, creating a vicious cycle. First, the current understanding of the pathogenesis of SS is briefly described. Next, studies on oral dysbiosis in SS are reviewed, and evidence for bacterial infection of the SS-affected salivary glands is provided. Finally, how bacterial infection can contribute to innate and adaptive immune activation in SS is discussed.

**INTERPLAY OF INNATE AND ADAPTIVE IMMUNE RESPONSES IN THE PATHOGENESIS OF SS**

There are many excellent reviews about the pathogenesis of SS (2,5,6). Here, we briefly summarize the current understanding of the initiation and perpetuation of SS (Fig. 1).

**Genetic and environmental factors**

SS is thought to occur in genetically susceptible individuals when they are exposed to environmental triggers. As genetic factors, gene loci involved in B cell follicle organization and function (CXCR5, BLK, PRDM1), type I IFNs (IRF5), T cell activation (HLA, STAT4, IL12, KLRG1, SH2D2A, and NFAT5), and control of NF-κB activation (TNIP1 and TNFAIP3) have been identified from 3 large-scale genome-wide association studies (2).

Suggested environmental factors include estrogen deficiency, infection with exogenous viruses, and overexpression of endogenous retroviruses (2,6,7).

Upregulation of endogenous retrovirus RNAs has been shown in mouse B cells after B cell receptor (BCR) crosslinking by T-cell-independent type 2 antigens (8). This suggests that the overexpressed endogenous retrovirus may contribute to the development of autoimmune diseases (2). Although an increased prevalence of human endogenous retrovirus HERV-K113 in SS patients in the United Kingdom has been reported (9), overexpression of HERV in the salivary glands or peripheral blood B cells has not been shown.
Human T-cell leukemia virus type 1 (HTLV-1) infects T cells and is a causative agent of adult T-cell leukemia and HTLV-1-associated myelopathy. Increased prevalence of HTLV-1 infection in SS patients compared with a general population has been repeatedly reported, together with the detection of HTLV-1 genes and proteins in the SS salivary glands (10). In addition, cultured salivary gland epithelial cells (SGECs) can be infected with HTLV-1 after coculture with an HTLV-1-infected T-cell line, which increases the expression of ICAM-1, CCL5, and CXCL10 in SGECs (11).

Epstein-Barr virus (EBV) has been extensively studied in association with SS because EBV mimics the key pathways of B-cell activation, such as BCR and CD40. EBV infects B cells and remains latent in resting memory B cells. Latent EBV can be reactivated upon BCR stimulation and undergo lytic replication in plasma cells. EBV DNA has been detected at increased levels in SS salivary glands (12). Interestingly, lytic EBV infection was observed exclusively in the SS salivary gland with ectopic lymphoid structures, and SSA/Ro52-reactive plasma cells were frequently infected with EBV (13). EBV-infected cells release EBV-encoded small RNA as a complex with SSB/La that induces TLR3 activation and the production of type I IFN (14). High titers of IgG against the EBV early antigen, a serologic marker of EBV...
reactivation, were associated with anti-SSA/SSB status and B-cell activation markers, but there was no evidence of systemic EBV reactivation in SS patients (15). In addition, EBV can infect oral epithelial cells through an interaction between the EBV BMRF-2 protein and α5β1 integrins at the basolateral membranes of the polarized epithelial cells or by direct cell-to-cell contact of apical cell membranes with EBV-infected lymphocytes (16). Notably, over 90% of the general population worldwide has latent EBV infection, and EBV DNA is commonly detected in the saliva or oral washes of healthy individuals (17). Why only a small proportion of these individuals results in SS development needs to be explained.

Collectively, how viral infections might trigger SS remains unclear. All viruses implicated in SS primarily infect lymphocytes. Although HTLV-1 and EBV can infect epithelial cells, they are likely to be mediated by virus-infected T or B cells recruited to the salivary glands. Therefore, virus infection may contribute to the perpetuation of inflammation rather than triggering it in the salivary glands.

The innate arm of SS pathogenesis
Accumulating evidence indicates that epithelial cells in SS lesions are not only the target of autoimmunity but also active participants in the induction of the inflammatory process. Diverse abnormalities have been found in the salivary gland epithelium of patients with SS (6). Changes in the acinar epithelium include i) dyslocalized proteins involved in the secretory machinery (PIP2, synaptotagmin 1, and AQPs), ii) mislocalization of mucins from the apical to the basal pole, iii) production of proinflammatory cytokines, and iv) disorganized basal lamina. Changes in the ductal epithelium include i) production of cytokines (IL-1, IL-6, IL-7, IL-18, TNFα, IFNα/β, and BAFF) and chemokines (CCL3, CCL4, CCL5, CXCL9, CXCL10, CXCL11, and CXCL12), ii) upregulated expression of molecules involved in antigen presentation (HLA-ABC, HLA-DR, CD80, CD86, ICAM-1, and VCAM-1), iii) disorganized basal lamina, iv) senescence of salivary gland progenitor cells, v) increased susceptibility to programmed cell death, and vi) increased expression of SS-associated autoantigens (SSA/Ro60, SSA/Ro52, SSB/La). Importantly, the expression of ICAM-1 on epithelial cells and cytokine production were shown to precede FLS and hyposalivation in nonobese diabetic mouse model of SS, suggesting that the innate activation of salivary gland epithelium orchestrates the adaptive arm of SS pathology (18).

Chemokines expressed by ductal cells might be responsible for the periductal recruitment of T cells, B cells, and dendritic cells (DCs). In particular, infiltration of the ductal epithelium with disrupted basal lamina by CD4+ T cells, CD8+ T cells, and B cells and formation of lymphoepithelial lesions are unique to the salivary glands in SS (19,20). As potent producers of IFNα, plasmacytoid DCs (pDCs) detected in the SS-affected salivary glands are believed to play a central role in maintaining the well-known IFN signature of SS (21). IFNα activates ductal epithelial cells, DCs, and T cells to produce cytokines (IL-7 and BAFF) and chemokines (CXCL10).

The adaptive arm of SS pathogenesis
pDCs can also present antigens to T cells, activating the recruited T cells in situ (22,23). Recruited T cells interact with epithelial cells and further activate epithelial cells via cytokines (IFNγ, TNF, IL-1β), establishing a positive inflammatory loop via the IL-7/IFN axis (24). CD8+ T cell-mediated apoptosis of epithelial cells might contribute to the exposure of intracellular autoantigens.

The SS-affected salivary glands provide a favorable microenvironment for the activation and survival of B cells (reviewed in 2). BAFF and IL-6 produced by epithelial cells are involved in B
cell activation and survival. BAFF is a key cytokine that promotes the proliferation and survival of B cells. pDCs can induce plasma cell differentiation of activated B cells through IFNα and IL-6 [23]. Cultured SGECs from patients with SS can support the in vitro differentiation of follicular Th cells through IL-6 and ICOSL [25], which play a pivotal role in ectopic germinal center formation [26]. Ectopic germinal centers function as niches for autoreactive B-cells in SS. Finally, CXCL-12 and IL-6 produced by epithelial and stromal cells can support the survival of long-lived plasma cells, forming a plasma cell niche [27]. The presence of anti-SSA and anti-SSB autoantibody-producing cells in the SS-affected salivary glands is correlated with the presence of autoantibodies in sera, suggesting that the salivary glands also provide a niche for autoantibody-secreting cells [28]. The apoptotic bodies of epithelial cells complexed with anti-SSA autoantibodies may continuously stimulate RF-expressing B cells through dual engagement of BCR and TLR7, which is likely to be crucial in lymphomagenesis [2,29].

DYSBIOSIS OF ORAL MICROBIOTA IN SS

There are 12 studies that investigated SS-specific changes in oral microbiota using a next-generation sequencing approach [30-41]. Except for one study that reported discriminatory taxa of supragingival plaque only at the species level [41], 10 studies reported significantly increased or decreased phyla and genera in the microbiota from buccal swabs, saliva, or oral washes, but one study reported no differentially distributed taxa (Table 1). SS-associated taxa can vary depending on the compared control group, sample size, sampling site, sequenced region of the 16S rRNA gene, threshold set for statistical significance, and geographic location. Six of 11 studies reported significant changes in the relative abundance of several phyla. An increase in Firmicutes and a decrease in Fusobacteria, Proteobacteria, and Spirochetes were reported in 2 or more studies (Fig. 2A). Although reduced Proteobacteria abundance in SS was reported in 3 studies, one study reported the opposite result. This finding may be attributed to the fact that Proteobacteria includes several genera increased as well as those decreased in SS (Fig. 2B). The genera significantly increased or decreased in ≥ 2 studies are presented in Fig. 2C. Changes in Lactobacillus (increase), Haemophilus (decrease), and Neisseria (decrease) were most frequently observed, the abundance of which is significantly correlated with stimulated whole salivary secretion [33]. Clearly, reduced salivary secretion seems to contribute more to the oral dysbiosis of SS than underlying disease does in comparison with healthy controls [33]. However, changes in the genera Bifidobacterium, Abiotrophia, and Granulicatella that were significant after adjusting for the stimulated whole salivary secretion rate were also observed in ≥ 2 studies (Fig. 2C). Two studies that investigated the SS and control groups with comparable levels of unstimulated whole salivary secretion rates by sequencing the V1–V3 regions of the 16S rRNA gene reported common changes, such as increases in Firmicutes and Streptococcus and decreases in Spirochaetes, Moryella, Porphyromonas, Tannerella, and Treponema [31,39].

Immunopathological implications of oral dysbiosis in SS

Only 2 groups further investigated the potential immunopathological sequelae of oral dysbiosis observed in SS. We tested 3 SS-associated (i.e., increased in SS) species for their ability to dysregulate human submandibular gland tumor (HSG). Two SS-associated species, Prevotella melaninogena and Rothia mucilaginosa, efficiently invaded HSG cells. Furthermore, while P. melaninogena induced upregulation of MHC molecules and CD80, R. mucilaginosa induced hypoxic cell death and downregulation of MHC I and CD86 [39,42]. Tseng et al. [40] reported that A253 cells pretreated with Haemophilus parainfluenzae, a species reduced in SS
| Studies | Sample size | Sampling site | Sequenced region of the 16S rRNA gene | Threshold set for statistical significance | Geographical site | Phylum | Genus |
|---------|-------------|--------------|--------------------------------------|------------------------------------------|------------------|--------|-------|
| Li et al., 2016 (30) | SS (n=10)/Hc (n=10) | Buccal swab | V1–V3 | p<0.05 | China | Proteobacteria | Delftia (Proteobacteria) |
| | | | | | | | Leucoacter (Actinobacteria) |
| | | | | | | Mitsuaria (Proteobacteria) |
| | | | | | | Pseudochrobactrum (Proteobacteria) |
| | | | | | | Ralstonia (Proteobacteria) |
| Siddiqui et al., 2016 (31) | SS (n=9 with normal salivation)/Hc (n=9) | Saliva | V1–V3 | q threshold not reported | Norway | Firmicutes | Synergistetes |
| | | | | | | | Streptococcus (Firmicutes) |
| van der Meulen et al., 2018 (32) | SS (n=37)/non-SS sicca (n=86)/Hc (n=24) | Buccal swab | V4 | q=0.1 | Netherlands | Proteobacteria | Alloscardovia (Actinobacteria) |
| | | | | | | | Anaeroglobus (Firmicutes) |
| | | | | | | | Atopobium (Actinobacteria) |
| | | | | | | | Bifidobacterium (Actinobacteria) |
| | | | | | | | Dialister (Firmicutes) |
| | | | | | | | Lactobacillus (Firmicutes) |
| | | | | | | | Parvimonas (Firmicutes) (Firmicutes) |
| | | | | | | | Peptostreptococcaceae (Firmicutes) |
| | | | | | | | Scardovia (Actinobacteria) |
| | | | | | | | Granulicatella (Firmicutes) |
| | | | | | | | Haemophilus (Proteobacteria) |
| | | | | | | | Morseyella (Firmicutes) |
| | | | | | | | Peptostreptococcaceae (Firmicutes) |
| | | | | | | | Porphyromonas (Bacteroidetes) |
| | | | | | | | Tannerella (Bacteroidetes) |
| | | | | | | | Treponema (Spirochaetes) |
| van der Meulen et al., 2018 (33) | SS (n=36)/non-SS sicca (n=85)/Hc (n=14) | Oral wash | V4 | q=0.1 | Netherlands | Proteobacteria | Abiotrophia (Firmicutes) |
| | | | | | | | Alloprevotella (Bacteroidetes) |
| | | | | | | | Bacteroides (Bacteroides) |
| | | | | | | | Enterococcus (Firmicutes) |
| | | | | | | | Granulicatella (Firmicutes) |
| | | | | | | | Haemophilus (Proteobacteria) |
| | | | | | | | Lautropia (Proteobacteria) |
| | | | | | | | Neisseria (Proteobacteria) |
| | | | | | | | Ruminococcaceae_G1 (Firmicutes) |
| Zhou et al., 2018 (34) | SS (n=22)/Hc (n=23) | Oral wash | V3–V4 | p<0.05 & LDA>4 | China | Proteobacteria | Actinomyces (Actinobacteria) |
| | | | | | | | Haemophilus (Proteobacteria) |
| | | | | | | | Neisseria (Proteobacteria) |
| | | | | | | | Peptostreptococcus (Firmicutes) |
| | | | | | | | Porphyromonas (Bacteroidetes) |
| | | | | | | | Rothia (Actinobacteria) |
| Rusthen et al., 2019 (35) | SS (n=15)/non-SS sicca (n=15)/Hc (n=15) | Saliva | 16S rRNA gene | p<0.05 with Bonferroni correction | Norway | Proteobacteria | Actinomyces (Actinobacteria) |
| | | | | | | | Haemophilus (Proteobacteria) |
| | | | | | | | Neisseria (Proteobacteria) |
| | | | | | | | Porphyromonas (Bacteroidetes) |
| | | | | | | | Rothia (Actinobacteria) |

(continued to the next page)
Table 1. (Continued) Dysbiosis of the oral microbiome observed in SS

| Studies            | Sample size                          | Sampling site          | Sequenced region of the 16S rRNA gene | Threshold set for statistical significance | Geographical site | Phylum            | Phylum | Phylum | Genus           | Decreased |
|--------------------|--------------------------------------|------------------------|---------------------------------------|--------------------------------------------|-------------------|-------------------|--------|--------|------------------|-----------|
| Sembler-Møller et al., 2019 (36) | SS (n=24)/non-SS sicca (n=34)        | Saliva                | 16S rRNA gene V1–V3                  | q threshold not reported                   | Denmark           | None              | None   | None   | None             | None      |
| van der Meulen et al., 2019 (37)    | SS (n=39)/SLE (n=30)/Hc (n=965)       | Buccal swab, oral wash | V4                                   | q<0.1                                      | Netherlands       | In SS (vs. SLE)  | Firmicutes | None   | Proteobacteria   | Lactobacillus (Firmicutes) |
| Sharma et al., 2020 (38)             | SS (n=37)/Hc (n=35)                  | Saliva                | V3–V4                                | p<0.05 & | fold change|>2       | India             | Bifidobacterium (Actinobacteria) | Leptotrichia (Fusobacteria) |
| Alam et al., 2020 (39)               | SS (n=25, including 8 with normal salivation)/Con (n=25, including 11 non-SS sicca) | Oral wash              | V1–V3                                | q<0.2                                      | Korea             | Firmicutes | Proteobacteria | Fusobacteria | Lactobacillus (Firmicutes) |
| Tseng et al., 2021 (40)              | SS (n=8)/Hc (n=16)                   | Saliva                | V3–V4                                | p<0.05                                     | Taiwan            | Atopobium (Actinobacteria) | Lactobacillus (Firmicutes) | Campylobacter (Proteobacteria) |

Hc, healthy controls; non-SS sicca, with dryness symptoms similar to those of primary SS patients but not fulfilling the criteria; LDA, low disease activity; SLE, systemic lupus erythematosus. *Significant taking into account smoking, dental status, and stimulated whole salivary secretion rate.
EVIDENCE FOR BACTERIAL INFECTION OF THE SALIVARY GLANDS IN SS

Recently, we reported the presence of bacteria within the ductal epithelium and the areas of infiltration in the labial salivary glands from patients with SS (39; Fig. 3). The bacterial infection of the salivary glands in SS is further supported by the increased expression of bacteria-sensing TLRs. Increased in situ expression of the TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 proteins in the salivary gland biopsies of SS patients has been reported (43-46). Increased expression of the TLR1, TLR2, and TLR4 genes in SS-SGECs compared to control-SGECs was also reported (47). Furthermore, stimulation of SGECs with ligands to TLR2, TLR3, and TLR4 in vitro significantly upregulated the expression of the respective TLR genes, suggesting that the increased TLR expression observed in vivo implies the triggered status of the molecule in situ (47). Interestingly, strong expression of TLRs (TLR2, TLR4, TLR6, TLR7, and TLR9) was observed in infiltrating mononuclear cells and ductal epithelial cells, which coincides with the pattern of bacterial infection (39,44,45).

Figure 2. Significantly altered phyla and genera reported in 11 studies on the oral microbiome of patients with SS. (A) Phyla significantly increased or decreased in the indicated number of studies. (B) The list of genera significantly increased or decreased in SS that belong to either Firmicutes or Proteobacteria. (C) Genera significantly increased or decreased in the indicated number of studies (only the genera reported in 2 or more studies are shown).
Figure 3. Bacterial infection and TLR4 expression in labial salivary gland biopsies. (A) In the labial salivary glands with focal lymphocytic sialadenitis from patients with SS, strong bacterial infection and TLR4 expression are observed not only at the area of lymphocytic infiltration and the ducts and acini nearby but also at the ducts without infiltration. (B) In labial salivary glands with nonspecific chronic inflammation from control subjects who did not meet the diagnostic criteria for SS, bacterial infection and TLR4 expression are observed only at the ducts with inflammation. Areas marked with rectangles in the image with low magnification are taken with high magnification. ‘a’ indicate acinus, ‘d’ indicate duct. Acini and ducts infected with bacteria are marked with the letter of dark violet, while uninfected ducts are marked in dark gray. Arrows indicate representative signals of bacteria. Scale bars: 50 µm.
To date, only viral pathogen-associated molecular patterns (PAMPs) or endogenous danger-associated molecular patterns have been considered ligands for the TLRs observed in SS-affected salivary glands (44,47,48). TLR3 and TLR7/TLR8 are known to recognize viral dsRNA and ssRNA, respectively (49). However, accumulating evidence shows that these TLRs also sense bacterial RNAs and induce type I IFN and NF-κB-dependent cytokines in monocytes, macrophages, pDCs, myeloid DCs, and keratinocytes (50-52). Therefore, bacterial PAMPs can trigger all TLRs expressed in the salivary glands and induce the activation of NF-κB, IRF3, and IRF7 (Fig. 4). In particular, the bacteria that can invade epithelial cells are likely to activate both surface and endosomal TLRs, resulting in the induction of proinflammatory cytokines and type I IFN (53).

Lewis et al. (54) reported the isolation of bacteria from stimulated parotid saliva collected from healthy individuals and patients with SS using modified Carlsson-Crittenden cups. In the culture of 3 consecutive 0.5 ml samples, the mean viable concentration of bacteria rapidly fell in the healthy group from 6.9×10³ to 0.3×10³ colony forming units (cfu)/ml, suggesting the cleansing effect of salivary secretion. Although the third sample could be collected from only 5 of 14 patients with SS due to the reduced salivary flow rate, a much higher number of bacteria (2.6×10³ cfu/ml) was detected in the samples (54). Reduction in salivary secretion indicates loss of the antimicrobial activity of the saliva. Furthermore, the expression of human β-defensins 1 and 2 was decreased in the salivary glands of patients with SS compared with those from healthy subjects (55). Significantly higher total bacterial loads of oral

**Figure 4.** The ligands and signaling pathways of TLRs expressed in the salivary glands of patients with SS.
bacterial communities in the SS group than in the control group have been reported even for the subgroup without oral dryness (39). These studies suggest that the ducts of the salivary glands normally have a microbial flora in health but the reduced mechanical flushing and salivary antimicrobial proteins/peptides in SS might provide a favorable environment for the bacterial infection of ductal epithelial cells.

**THE CONTRIBUTION OF BACTERIAL INFECTION TO INNATE IMMUNE ACTIVATION**

Bacterial infection of the salivary glands might contribute to the innate arm of SS pathology via interaction with 3 cell types: epithelial cells, pDCs, and B cells.

**Contribution to dysregulation of epithelial cells**

Stimulation of cultured SGECs with ligands for TLR2, TLR3, TLR4, or TLR7 increases the expression of HLA class I, ICAM-1, and CD40 (46,47). In addition, stimulation of SGECs with ligands for TLR2 or TLR3 induces the production of cytokines, such as IL-45, IL-7, IFNβ, and BAFF (24,56,57). The disorganized basal lamina observed in the SS-affected salivary glands is associated with increased levels of MMP-9 expression and activity in epithelial cells, and the expression of MMP-9 is dependent on NF-κB (58,59). Periodontitis-associated bacteria induce MMP-9 in gingival epithelial cells (60,61). Likewise, bacterial infection may induce MMP-9 expression in SGECs. Furthermore, a number of oral bacterial species produces cell-bound and extracellular proteinases that activate proMMP-9 and degrade laminin and collagens (62,63).

Notably, the expression of HLA-DR, CD86, ICAM-1, VCAM-1, IFNα/β, CXCL9, CXCL10, and CXCL11 is predominantly observed on ductal cells associated with heavy lymphocytic infiltration (46,64-66), while the expression of CCL3, CCL4, CCL5, and MMP-9 on ductal cells is independent of infiltration (58,64,67). Heavy bacterial infection and strong TLR4 expression were observed not only in the ducts near lymphocytic infiltration but also in those without infiltration in the SS salivary glands with FLS (39; Fig. 3). Gram-negative bacteria that invade ductal epithelial cells are expected to activate both NF-κB and IRFs (Fig. 4). Bacterial infection of ductal cells might preferentially upregulate the expression of molecules that mainly depends on NF-κB and IRF3, such as CCL3, CCL4, CCL-5 and MMP-9, contributing to the initial recruitment of T cells. The recruited T cells then contribute to the IFNγ-dependent expression of HLA-DR, CD86, CXCL9, CXCL10, and CXCL11.

The possibility that bacterial infection induces pyroptosis, apoptosis, and necroptosis in host cells should also be considered (68). Bacteria-induced cell death would contribute to not only the release of intracellular autoantigens but also barrier dysfunction.

**Contribution to activation of pDCs**

pDCs preferentially express TLR7 and TLR9. In the SS-affected salivary glands, pDCs might be exposed to bacterial nucleic acids by extracellular vesicles or bacteria that have crossed the epithelial barrier. Not only extracellular vesicles secreted by bacteria but also those secreted by host cells infected with bacteria contain immunostimulatory DNA, RNA, and other PAMPs (69,70). pDCs are expected to take up both bacteria (either free form or immune complex) and extracellular vesicles by micropinocytosis or endocytosis, which would contribute to the maturation of pDCs and sustained production of IFNα via TLR7 and TLR9 (Figs. 1 and 4).
Contribution to innate activation of B cells and plasma cells

The SS-affected salivary glands are enriched with CD27+ memory B cells and fully differentiated plasma cells (71). Human memory B cells express substantial levels of TLR1, TLR6, TLR7, TLR9, and TLR10 and low levels of TLR2 (72-74). Human B cells upregulate the expression of antigen presenting molecules (HLA-DR, CD80, and CD86) and secrete cytokines (IL-1α, IL-6, IL-10) in response to stimulation of TLR1/2, TLR7, and TLR9 (73,75). In addition, TLR9 stimulation can induce strong polyclonal B cell proliferation and antibody secretion from memory B cells in the absence of BCR signaling (72). TLR7 ligands can also induce polyclonal B cell proliferation in the presence of IFNα (76). Unlike pDCs, B cells internalize exogenous materials mainly through BCRs (2). Therefore, only RF+ B cells that infiltrate the SS-affected salivary glands may access bacterial nucleic acids in the form of immune complexes. Whether extracellular vesicles containing bacterial nucleic acids can stimulate B cells needs to be verified. In contrast to B cells, human plasma cells express all TLRs, including TLR3 and TLR4, and stimulation of TLRs on plasma cells enhances antibody secretion (74). The endocytic ability of plasma cells has been reported (76). Therefore, bacteria are likely to stimulate plasma cells not only through the TLRs expressed on the cell surface, such as TLR2, TLR4, and TLR5, but also through endosomal TLRs. Collectively, bacterial infection of the salivary glands would contribute to the B cell hyperactivity and hypergammaglobulinemia of SS.

THE CONTRIBUTION OF BACTERIAL INFECTION TO ADAPTIVE IMMUNE ACTIVATION

Bacterial infection of the salivary glands may contribute to the adaptive arm of SS pathology via 3 mechanisms: molecular mimicry, bystander activation of autoreactive T cells by activated antigen-presenting cells (APCs), and T-cell-mediated pathology.

Molecular mimicry

The potential role of bacterial orthologs identified in human-associated bacteria in breaching tolerance to autoantigens was previously proposed (77). A recent study identified Ro60 orthologs (bacterial ribonucleoprotein) in human commensal bacterial species and clearly showed molecular mimicry between the human Ro60 and bacterial orthologs (78). Human Ro60 autoantigen-specific CD4 memory T cells from patients with systemic lupus erythematosus were activated by Ro60 ortholog-containing bacteria, and anti-Ro60-positive sera bound recombinantly expressed bacterial Ro60 orthologs. Furthermore, monoclonization of germ-free mice with a Ro60 ortholog-containing gut commensal spontaneously induced anti-human Ro60 T- and B-cell responses. Among the Ro60 orthologs, the top 3 species (Corynebacterium amycolatum, Propionibacterium propionicum, and Actinomyces massiliensis) closest to human Ro60 have remarkably high sequence homology with Ro60 both at the early B-cell epitope and a major T-cell epitope, 85% and 70%, respectively. P. propionicum and A. massiliensis, as oral commensals, are isolated from parotid saliva (54). P. propionicum is also a member of ocular commensals (79). Bacterial orthologs for AQPS, an SS-specific autoantigen, have also been identified in human oral commensal bacterial species (80,81). Repeated immunization with a peptide derived from the AQP of P. melaninogena, which has 91% and 71% homology with a functional B cell epitope and an overlapping T cell epitope of human AQPS, respectively, induced anti-AQPS autoantibodies and hyposalivation in C57BL/6 mice (82). Importantly, P. melaninogena was detected within ductal cells and periductal infiltrates in the labial salivary glands of patients with SS (39). Although the...
evidence for the association of *P. propionicum*, *A. massiliensis*, or *P. melaninogenica* with SS is currently insufficient, the bacterial orthologs of Ro60 or AQP5 might drive the development of autoantibodies in SS before the onset of symptoms.

**Bystander activation of autoreactive T cells by activated APCs**

The recruitment and maturation of DCs, including pDCs, in the salivary glands have been regarded as inappropriate. To date, viral infection or RNA-containing immune complexes have been suggested as sources that activate pDCs. However, bacterial infection can also induce the recruitment and activation of DCs. In addition, B cells are especially efficient in presenting particulate antigens, such as virus-like particles and bacteria (83). APCs activated during microbial infection can present autoantigens as well as microbial antigens, so-called “bystander activation of autoreactive T cells” (84). The breach of T-cell tolerance against autoantigens is likely to occur when T cells are repeatedly exposed to autoantigens presented by activated DCs or B cells in the setting of chronic infection.

**T-cell-mediated pathology**

TLR signaling by microbial components induces phagosomal delivery of MHC class I molecules from the endosomal recycling compartment and allows cross-presentation in myeloid DCs (85). Ductal epithelial cells may cross-present internalized bacterial antigens to bacteria-specific CD8⁺ T cells, contributing to increased apoptosis. Since the ductal epithelium in SS-affected salivary glands often expresses MHC class II molecules, presentation to bacteria-specific Th1 cells is also expected. The Th1 cytokines IFNγ and TNFα disrupt an epithelial physical barrier (86). Altogether, crosstalk between bacteria-infected epithelial cells and bacteria-specific effector T cells will disrupt the epithelial barrier, facilitating continuous infection.

**CONCLUSIONS AND FUTURE DIRECTION**

Saliva strongly affects the ecology of the oral microbiome. Thus, the dysbiosis of the oral microbiome observed in SS patients with reduced salivary secretion is attributed more to oral dryness than to the underlying disease. Notably, correction of a dysbiotic oral microbiota in IκB-ζ-deficient mice through cohousing with wild-type mice alleviates the development of FLS, suggesting the role of oral dysbiosis in the development of SS in a mouse model (87).

Nevertheless, it is not yet clear whether oral dysbiosis causes bacterial infection of the ductal epithelium in SS-affected salivary glands. Although 2 of 3 SS-associated species efficiently invade HSG cells (39), there is a possibility that the bacteria infecting the salivary glands are not necessarily increased in the oral cavity of SS patients. A balance between epithelium-invading and noninvading taxa might be important. In addition, whether bacterial infection is the primary cause of SS or the result of oral dryness is not clear. Importantly, the reduced salivary secretion produces an environment that can facilitate bacterial infection of the ductal epithelium in the salivary glands. Therefore, bacterial infection of the salivary glands can lead to a vicious cycle of SS pathogenesis via innate and adaptive activation of epithelial cells and immune cells (Fig. 5A).

In conclusion, we propose that bacterial infection of the salivary glands may play an important role in the perpetuation of sialadenitis and autoantibody production in SS. Many parts of this idea need experimental verification. Characterization of the bacterial
taxa present within the salivary glands of SS patients would be most important for future studies. Other valuable questions, including a cross-kingdom interaction between bacteria and viruses within the salivary glands, are listed (Fig. 5B). Future therapeutics must consider breaking the vicious cycle of SS pathogenesis involving bacterial infection.

ACKNOWLEDGEMENTS

This study was supported by the National Research Foundation of Korea (Daejun, Korea) through the grants 2018R1A5A2024418 and 2020R1A2C2007038 awarded to Youngnim Choi and a grant 2020R1A2C1100163 awarded to Sung-Ho Chang.

REFERENCES

1. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M. Sjögren syndrome. Nat Rev Dis Primers 2016;2:16047.

2. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol 2018;14:133-145.
3. Shiboski CH, Shiboski SC, Seroor R, Criswell LA, Labetoulle M, Liemtan TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis* 2017;76:9-16. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

4. Martín-Nares E, Hernández-Molina G. Novel autoantibodies in Sjögren’s syndrome: a comprehensive review. *Autoimmun Rev* 2019;18:192-198. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

5. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren’s syndrome. *Nat Rev Rheumatol* 2010;6:529-537. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

6. Verstappen GM, Pringle S, Bootsma H, Kroese FG. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. *Nat Rev Rheumatol* 2021;17:333-348. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

7. Konttinen YT, Stegajev V, Al-Samadi A, Porola P, Hietanen J, Ainola M. Sjögren’s syndrome and extragonadal sex steroid formation: a clue to a better disease control? *J Steroid Biochem Mol Biol* 2015;145:237-244. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

8. Zeng M, Hu Z, Shi X, Li X, Zhan X, Li XD, Wang J, Choi JH, Wang KW, Purrington T, et al. MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses. *Science* 2014;346:1486-1492. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

9. Nakamura H, Shimizu T, Kawakami A. Role of viral infections in the pathogenesis of Sjögren’s syndrome: different characteristics of Epstein-Barr virus and HTLV-I. *J Clin Med* 2020;9:1459. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

10. Nakamura H, Takahashi Y, Yamamoto-Fukuda T, Horal Y, Nakashima Y, Arima K, Nakamura T, Koji T, Kawakami A. Direct infection of primary salivary gland epithelial cells by human T lymphotropic virus type I in patients with Sjögren’s syndrome. *Arthritis Rheumatol* 2015;67:1096-1106. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

11. Mariette X, Gozlan J, Clerc D, Bisson M, Morinet F. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren’s syndrome. *Am J Med* 1991;90:286-294. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

12. Sanosyan A, Daien C, Nutz A, Bollore K, Bedin AS, Morel J, Zimmermann V, Nocturne G, Peries M, Guigue N, et al. Discrepancy of serological and molecular patterns of circulating Epstein-Barr virus reactivation in primary Sjogren’s syndrome. *Front Immunol* 2019;10:1153. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

13. Ikuta K, Satoh Y, Hoshikawa Y, Saijenji T. Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children. *Microbes Infect* 2000;2:115-120. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

14. Koecher N, Lodde BM, Vosters JL, Tak PP, Catalan MA, Illei GG, Chiorini JA. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren’s syndrome. *Oral Dis* 2012;18:96-106. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)

15. Molina C, Allende A, Aguieria S, Kwon YJ, Leyton L, Martinez B, Leyton C, Perez P, Gonzalez MJ. Basal lamina disorganisation of the acini and ducts of labial salivary glands from patients with Sjogren’s syndrome: association with mononuclear cell infiltration. *Ann Rheum Dis* 2006;65:178-183. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.4110/in.2022.22.e32)
van Ginkel MS, Haacke EA, Bootsma H, Arends S, van Nimwegen IF, Verstappen GM, Spijkervet FK, Vissink A, van der Vegt B, Kroese FG. Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients. *Clin Exp Rheumatol* 2019;37 Suppl 118:42-48.
PUBMED

Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. *Proc Natl Acad Sci U S A* 2006;103:2770-2775.
PUBMED | CROSSREF

Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. *Immunity* 2008;29:352-361.
PUBMED | CROSSREF

Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity* 2003;19:225-234.
PUBMED | CROSSREF

Rivière E, Pascaud J, Vironne A, Dupré A, Ly B, Paolletti A, Seror R, Tchitchek N, Mingueau M, Smith N, et al. Interleukin-7/interferon axis drives T cell and salivary gland epithelial cell interactions in Sjögren’s syndrome. *Arthritis Rheumatol* 2021;73:631-640.
PUBMED | CROSSREF

Gong YZ, Nititham J, Taylor K, Miceli-Richard C, Sordet C, Wachsmann D, Bahram S, Georgel P, Criswell LA, Sibilia J, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren’s syndrome. *Arthritis Rheumatol* 2021;73:631-640.
PUBMED | CROSSREF

Pontarini E, Murray-Brown WJ, Croia C, Lucchesi D, Conway J, Rivellesef E, Fossati-Jimack L, Astorri E, Prediletto E, Corsiero E, et al. Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma. *Ann Rheum Dis* 2020;79:1588-1599.
PUBMED | CROSSREF

Szyszko EA, Brokstad KA, Oijordsbakken G, Jonsson MV, Jonsson R, Skarstein K. Salivary glands of primary Sjögren’s syndrome patients express factors vital for plasma cell survival. *Arthritis Res Ther* 2011;13:R2.
PUBMED | CROSSREF

Tengner P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren’s syndrome. *Arthritis Rheum* 1998;41:2238-2248.
PUBMED | CROSSREF

Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Riklin IR, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. *J Exp Med* 2005;202:1171-1177.
PUBMED | CROSSREF

Li M, Zou Y, Jiang Q, Jiang L, Yu Q, Ding X, Yu Y. A preliminary study of the oral microbiota in Chinese patients with Sjögren’s syndrome. *Arch Oral Biol* 2016;70:143-148.
PUBMED | CROSSREF

Siddiqui H, Chen T, Aliko A, Mydel PM, Jonsson R, Olsen I. Microbiological and bioinformatics analysis of primary Sjögren’s syndrome patients with normal salivation. *J Oral Microbiol* 2016;8:e0218319.
PUBMED | CROSSREF

van der Meulen TA, Harmse HJ, Bootsma H, Liefers SC, Vich Vila A, Zhernakov A, Fu J, Wijnenga C, Spijkervet FK, Kroese FG, et al. Dysbiosis of the buccal mucosa microbiome in primary Sjögren’s syndrome patients. *Rheumatology (Oxford)* 2018;57:2225-2234.
PUBMED | CROSSREF

van der Meulen TA, Harmse HJ, Bootsma H, Liefers SC, Vich Vila A, Zhernakov A, Weersma RK, Spijkervet FK, Kroese FG, Vissink A. Reduced salivary secretion contributes more to changes in the oral microbiome of patients with primary Sjögren’s syndrome than underlying disease. *Ann Rheum Dis* 2018;77:1542-1544.
PUBMED | CROSSREF

Zhou Z, Ling G, Ding N, Xun Z, Zhu C, Hua H, Chen X. Molecular analysis of oral microflora in patients with primary Sjögren’s syndrome by using high-throughput sequencing. *Perf J* 2018;6:e5649.
PUBMED | CROSSREF

Rusthen S, Kristoffersen AK, Young A, Galtung HK, Petrovski BE, Palm Ø, Enersen M, Jensen JL. Dysbiotic salivary microbiota in dry mouth and primary Sjögren’s syndrome patients. *PLoS One* 2019;14:e0218319.
PUBMED | CROSSREF
36. Sembler-Møller ML, Belstrøm D, Locht H, Enevold C, Pedersen AM. Next-generation sequencing of whole saliva from patients with primary Sjögren’s syndrome and non-Sjögren’s sicca reveals comparable salivary microbiota. *J Oral Microbiol* 2019;11:1660566.

37. van der Meulen TA, Harmsen HJ, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A, Fu J, Wijnenga C, Weersma RK, de Leeuw K, et al. Shared gut, but distinct oral microbiota composition in primary Sjögren’s syndrome and systemic lupus erythematosus. *J Autoimmun* 2019;97:77-87.

38. Sharma D, Sandhya P, Vellarikkal SK, Surin AK, Jayarajan R, Verma A, Kumar A, Ravi R, Danda D, Sivasubbu S, et al. Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes. *Oral Dis* 2020;26:295-301.

39. Alam J, Lee A, Lee J, Kwon DI, Park HK, Park JH, Jeon S, Baek K, Lee J, Park SH, et al. Dysbiotic oral microbiota and infected salivary glands in Sjögren’s syndrome. *PLoS One* 2020;15:e0230667.

40. Tseng YC, Yang HY, Lin WT, Chang CB, Chien HC, Wang HP, Chen CM, Wang JT, Li C, Wu SF, et al. Salivary dysbiosis in Sjögren’s syndrome and a commensal-mediated immunomodulatory effect of salivary gland epithelial cells. *NPJ Biofilms Microbiomes* 2021;7:21.

41. Palmer RJ, Cotton SL, Kokaras AS, Gardner P, Grisius M, Pelayo E, Warner B, Paster BJ, Alevizos I. Analysis of oral bacterial communities: comparison of HOMI_NGS with a tree-based approach implemented in QIIME. *J Oral Microbiol* 2019;11:1586413.

42. Lee J, Jeon S, Choi Y. Two Sjogren syndrome-associated oral bacteria, *Prevotella melaninogenica* and *Rothia mucilaginosa*, induce the upregulation of major histocompatibility complex class I and hypoxia-associated cell death, respectively, in human salivary gland cells. *Int J Oral Biol* 2021;46:190-199.

43. Kawakami A, Nakashima K, Tamai M, Nakamura H, Iwanaga N, Fujikawa K, Aramaki T, Arima K, Iwamoto N, Ichinose K, et al. Toll-like receptor in salivary glands from patients with Sjögren’s syndrome: functional analysis by human salivary gland cell line. *J Rheumatol* 2007;34:1019-1026.

44. Zheng L, Zhang Z, Yu C, Yang C. Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren’s syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2010;109:844-850.

45. Kwok SK, Cho ML, Her YM, Oh HJ, Park MK, Lee SY, Woo YJ, Ju JH, Park KS, Kim HY, et al. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjögren’s syndrome. *Arthritis Res Ther* 2012;14:R64.

46. Shimizu T, Nakamura H, Takatani A, Umeda M, Horai Y, Kurushima S, Michitsuji T, Nakashima Y, Kawakami A. Activation of Toll-like receptor 7 signaling in labial salivary glands from patients with primary Sjögren’s syndrome. *Clin Exp Immunol* 2019;196:39-51.

47. Spachidou MP, Bourazopoulou E, Maratheftis CI, Kapsogeorgou EK, Moutsopoulos HM, Tsiofas AG, Manoussakis MN. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren’s syndrome. *Clin Exp Immunol* 2007;147:497-503.

48. Kirollosky J, Kramer JM. Current and emerging evidence for Toll-like receptor activation in Sjögren’s syndrome. *J Immunol Res* 2018;2018:1246818.

49. Uematsu S, Akira S. Toll-like receptors and Type I interferons. *J Biol Chem* 2007;282:15319-15323.

50. Campos PC, Gomes MT, Guimarães ES, Guimarães G, Oliveira SC. TLR7 and TLR3 sense *Brucella abortus* RNA to induce proinflammatory cytokine production but they are dispensable for host control of infection. *Front Immunol* 2017;8:28.

51. Cervantes JL, La Vake CJ, Weinerman B, Luu S, O’Connell C, Verardi PH, Salazar JC. Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes. *J Leukoc Biol* 2013;94:1231-1241.
52. Eigenbrod T, Dalpke AH. Bacterial RNA: an underestimated stimulus for innate immune responses. *J Immunol* 2015;195:411-418.

53. Pitha PM. Unexpected similarities in cellular responses to bacterial and viral invasion. *Proc Natl Acad Sci U S A* 2004;101:695-696.

54. Lewis MA, Macfarlane TW, Lanej PJ, Leishman RE, Howie NM. Quantitative bacteriology of the parotid salivary gland in health and Sjögren’s syndrome. *Microb Ecol Health Dis* 1993;6:29-34.

55. Kameda Y, Yamaai T, Mizukawa N, Nagatsuka H, Yamachika E, Gunduz M, Sawaki K, Yamanishi Y, Matsubara M, Katase N, et al. Localization of antimicrobial peptides human beta-defensins in minor salivary glands with Sjögren’s syndrome. *Eur J Oral Sci* 2009;117:506-510.

56. Sisto M, Lorusso L, Lisi S. TLR2 signals via NF-κB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren’s syndrome. *Clin Exp Med* 2017;17:341-350.

57. Ittah M, Miceli-Richard C, Gottenberg JE, Sellam J, Eid P, Lebon P, Paller C, Lepajoelc C, Mariette X. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. *Eur J Immunol* 2008;38:1058-1064.

58. Pérez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C, Pinto R, Romo R, Martinez B, González ML. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren’s syndrome. *Arthritis Rheum* 2002;46:1585-1594.

59. Gursoy UK, Könnönen E, Uitto VJ. Stimulation of epithelial cell matrix metalloproteinase (MMP-2, -9, -13) and interleukin-8 secretion by fusobacteria. *Oral Microbiol Immunol* 2008;23:432-434.

60. Singh B, Fleury C, Jalalvand F, Riesbeck K. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. *FEMS Microbiol Rev* 2012;36:1122-1180.

61. Ogawa N, Kawanami T, Shimoyama K, Pang L, Sugai S. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren’s syndrome. *Br J Rheumatol* 1998;37:779-783.
68. Jiang W, Deng Z, Dai X, Zhao W. PANoptosis: a new insight into oral infectious diseases. *Front Immunol* 2021;12:789610. [PUBMED] [CROSSREF]

69. Bitto NJ, Cheng L, Johnston EL, Pathirana R, Phan TK, Poon IK, O’Brien-Simpson NM, Hill AF, Stinear TP, Kaparakis-Liaskos M. *Staphylococcus aureus* membrane vesicles contain immunostimulatory DNA, RNA and peptidoglycan that activate innate immune receptors and induce autophagy. *J Extracell Vesicles* 2021;10:e12080. [PUBMED] [CROSSREF]

70. Cheng Y, Schorey JS. Extracellular vesicles deliver *Mycobacterium* RNA to promote host immunity and bacterial killing. *EMBO Rep* 2019;20:e46613. [PUBMED] [CROSSREF]

71. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dörner T. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. *Arthritis Rheum* 2002;46:2160-2171. [PUBMED] [CROSSREF]

72. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood* 2003;101:4500-4504. [PUBMED] [CROSSREF]

73. Månsson A, Adner M, Höckerfelt U, Cardell LO. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. *Immunology* 2006;118:539-548. [PUBMED] [CROSSREF]

74. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L, Berger C, Bernasconi M, Speck RF, Nadal D. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. *Immunology* 2009;128:573-579. [PUBMED] [CROSSREF]

75. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. *J Clin Immunol* 2011;31:89-98. [PUBMED] [CROSSREF]

76. Alm J, Kim YC, Choi Y. Potential role of bacterial infection in autoimmune diseases: a new aspect of molecular mimicry. *Immune Netw* 2014;14:7-13. [PUBMED] [CROSSREF]

77. Alam J, Koh JH, Kim N, Kwok SK, Park SH, Song YW, Park K, Choi Y. Detection of autoantibodies against aquaporin-5 in the sera of patients with primary Sjögren's syndrome. *Immunol Res* 2016;64:848-856. [PUBMED] [CROSSREF]

80. Alam J, Koh JH, Kim N, Kwok SK, Park SH, Song YW, Park K, Choi Y. Detection of autoantibodies against aquaporin-5 in the sera of patients with primary Sjögren’s syndrome. *Immunol Res* 2016;64:848-856. [PUBMED] [CROSSREF]

81. Lee A, Yoo DK, Lee Y, Jeon S, Jung S, Noh J, Ju S, Hwang S, Kim HH, Kwon S, et al. Induction of anti-aquaporin 5 autoantibody production by immunization with a peptide derived from the aquaporin of *Pseudomonas aeruginosa* leads to reduced salivary flow in mice. *Immune Netw* 2021;21:e34. [PUBMED] [CROSSREF]

82. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev* 2006;19:80-94. [PUBMED] [CROSSREF]
85. Nair-Gupta P, Baccarini A, Tung N, Seyffer F, Florey O, Huang Y, Banerjee M, Overholtzer M, Roche PA, Tampé R, et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. *Cell* 2014;158:506-521.

86. Li Q, Zhang Q, Wang M, Zhao S, Ma J, Luo N, Li N, Li Y, Xu G, Li I. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. *Clin Immunol* 2008;126:67-80.

87. Lee J, Alam J, Choi E, Ko YK, Lee A, Choi Y. Association of a dysbiotic oral microbiota with the development of focal lymphocytic sialadenitis in IκB-ζ-deficient mice. *NPJ Biofilms Microbiomes* 2020;6:49.